Results 181 to 190 of about 6,026,414 (311)

Cost-effectiveness of recommended interventions for managing low back pain: A systematic review. [PDF]

PLoS Med
Mathieson S, Underwood M, Ibrahim M, Hua Z, Zhu Z, Ferreira PH, Mistry H, Atkins ER, Bowden JL, Eyles JP, Briggs AM, Hunter DJ, Ferreira ML.   +12 more
europepmc   +1 more source

Subjective Cognitive Concerns and Cognitive Trajectories in Parkinson's Disease: Biomarker Impact

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To examine the relationship of subjective cognitive concerns (SCC) with biomarkers of Alzheimer's disease (AD), neurodegeneration, and Parkinson's disease (PD) and domain‐specific cognitive trajectories among cognitively unimpaired persons with de novo PD. Method Cognitively unimpaired participants with SCC (n = 294) and without SCC (
Francesca V. Lopez, Fareshte Erani, Katherine J. Bangen, David G. Coughlin, Douglas Galasko, Kelsey R. Thomas   +5 more
wiley   +1 more source

The Estimated Health System Cost Impacts of Interventions to Reduce Alcohol Harm in New Zealand: A Modelling Study. [PDF]

Drug Alcohol Rev
Mizdrak A, Davies A, Cobiac L, Chambers T.   +3 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

Exergoeconomic, Exergoenvironmental, and Renewability Assessment of Corn Stover and Sugarcane Bagasse PLA Biorefineries With Co-Product Valorization. [PDF]

Glob Chall
Hessampour R, Jahanian A, Ramirez J, O'Hara I.   +3 more
europepmc   +1 more source

Mining costs : related costs, construction costs, equipment costs

, 1971
openaire   +2 more sources

A Two‐Stage Plasma Biomarker Algorithm Reduces Amyloid PET Use and the p‐Tau217 Gray Zone

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma p‐Tau217 leaves 30%–50% of patients in an indeterminate “gray zone” often requiring Aβ‐PET. We developed GRAD (Gatekeeper‐Reflex for Alzheimer's Disease), a two‐stage Aβ‐positivity prediction model to improve classification while reserving Aβ‐PET for residual uncertainty.
Harthik Parankusham, Casey Vanderlip, Colin Birkenbihl, Eashwar Krishna, Chizobam Ugboaja, Andrew E. Budson, Brandon Frank, for the Alzheimer's Disease Neuroimaging Initiative   +7 more
wiley   +1 more source

Potential effect of real-world junk food and sugar-sweetened beverage taxes on population health, health system costs and greenhouse gas emissions in New Zealand: a modelling study

BMJ Nutrition, Prevention & Health
Tony Blakely, Anja Mizdrak, Cliona Ni Mhurchu, Amanda C Jones, Nhung Nghiem, Leah Grout, Christine Cleghorn   +6 more
doaj   +1 more source

Improving the Diagnostic Accuracy of Plasma Alzheimer's Disease Biomarkers With Objective and Subjective Cognitive Screening

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Blood‐based biomarkers are increasingly used to identify Alzheimer's disease (AD) pathology and may play an important role in early disease screening and participant selection for clinical trials. However, their performance across stages of cognitive impairment remains unclear. This study examined whether plasma biomarkers differ in
Maryam Abdolmaleki, Leslie S. Gaynor, Dandan Liu, Timothy J. Hohman, Katherine A. Gifford, Henrik Zetterberg, Angela L. Jefferson, Corey J. Bolton   +7 more
wiley   +1 more source

Restricting tobacco sales to only pharmacies as an endgame strategy: are pharmacies likely to opt in?

Australian and New Zealand Journal of Public Health, 2018
Frederieke Sanne Petrović‐van der Deen, Nick Wilson   +1 more
doaj   +1 more source